Gil Ben-Menachem, Steven M Ferguson, Krishna Balakrishnan
{"title":"超越专利和版税:与美国国立卫生研究院做生意的感知和现实。","authors":"Gil Ben-Menachem, Steven M Ferguson, Krishna Balakrishnan","doi":"10.1038/bioent895","DOIUrl":null,"url":null,"abstract":"<p><p>Young, and mid size biotech companies can benefit hugely from the US National Institutes of Health (NIH), not least because of the agency's non-dilutive funding, guidance, and opportunities for collaboration. Increasingly, however, there is a fair bit of misunderstanding about what the NIH can and cannot do for a biotech entrepreneur.</p>","PeriodicalId":83088,"journal":{"name":"The journal of biolaw & business","volume":"24 1","pages":"17-20"},"PeriodicalIF":0.0000,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/bioent895","citationCount":"4","resultStr":"{\"title\":\"Beyond Patents and Royalties: Perception and Reality of Doing Business with the NIH.\",\"authors\":\"Gil Ben-Menachem, Steven M Ferguson, Krishna Balakrishnan\",\"doi\":\"10.1038/bioent895\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Young, and mid size biotech companies can benefit hugely from the US National Institutes of Health (NIH), not least because of the agency's non-dilutive funding, guidance, and opportunities for collaboration. Increasingly, however, there is a fair bit of misunderstanding about what the NIH can and cannot do for a biotech entrepreneur.</p>\",\"PeriodicalId\":83088,\"journal\":{\"name\":\"The journal of biolaw & business\",\"volume\":\"24 1\",\"pages\":\"17-20\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1038/bioent895\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The journal of biolaw & business\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1038/bioent895\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of biolaw & business","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/bioent895","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Beyond Patents and Royalties: Perception and Reality of Doing Business with the NIH.
Young, and mid size biotech companies can benefit hugely from the US National Institutes of Health (NIH), not least because of the agency's non-dilutive funding, guidance, and opportunities for collaboration. Increasingly, however, there is a fair bit of misunderstanding about what the NIH can and cannot do for a biotech entrepreneur.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
